Valuation: Spectral Medical Inc.

Capitalization 40Cr 29Cr 25Cr 23Cr 22Cr 2.74TCr 41Cr 270.14Cr 105.71Cr 1.32TCr 110.42Cr 108.09Cr 4.67TCr P/E ratio 2026 *
-46x
P/E ratio 2027 * -
Enterprise value 40Cr 29Cr 25Cr 23Cr 22Cr 2.74TCr 41Cr 270.14Cr 105.71Cr 1.32TCr 110.42Cr 108.09Cr 4.67TCr EV / Sales 2026 *
152x
EV / Sales 2027 * 23.6x
Free-Float
68.61%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Spectral Medical Inc.

1 day+0.72%
1 week-0.71%
1 month+8.59%
3 months-4.79%
6 months-2.11%
Current year-3.47%
1 week 1.36
Extreme 1.36
1.41
1 month 1.21
Extreme 1.21
1.52
Current year 1.21
Extreme 1.21
1.52
1 year 0.74
Extreme 0.74
1.84
3 years 0.22
Extreme 0.225
1.84
5 years 0.15
Extreme 0.15
1.84
10 years 0.15
Extreme 0.15
2.07
Manager TitleAgeSince
Chief Executive Officer - 01/04/2021
Chief Tech/Sci/R&D Officer - 01/03/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman - 02/04/2024
Director/Board Member - 24/09/2014
Director/Board Member 73 31/05/2018
Change 5d. change 1-year change 3-years change Capi.($)
+0.72%-0.71%+87.84%+387.72% 29Cr
-0.76%-0.92%+22.29%+146.18% 83TCr
+0.90%+0.71%+55.55%+44.78% 57TCr
+1.84%+1.88%+17.40%+30.12% 37TCr
+0.54%-0.75%+29.45%+14.12% 32TCr
-0.47%-2.60%+49.06%+25.19% 31TCr
-0.16%+0.57%+51.52%+4.03% 30TCr
-0.28%-2.37%+39.71%+38.08% 29TCr
+0.32%+3.22%+19.40%+40.38% 19TCr
+1.02%+1.19%+31.88%+69.22% 17TCr
Average +0.71%-0.72%+40.41%+79.98% 33.55TCr
Weighted average by Cap. +0.51%-0.65%+35.06%+60.41%

Financials

2026 *2027 *
Net sales 26.7L 19.4L 16.44L 15.15L 14.3L 18Cr 27.18L 1.78Cr 69.71L 8.68Cr 72.81L 71.27L 31Cr 1.71Cr 1.25Cr 1.06Cr 97.29L 91.85L 116.03Cr 1.75Cr 11Cr 4.48Cr 56Cr 4.68Cr 4.58Cr 197.93Cr
Net income -1.19Cr -86.8L -73.56L -67.76L -63.97L -81Cr -1.22Cr -7.97Cr -3.12Cr -39Cr -3.26Cr -3.19Cr -137.85Cr 20T 14.53T 12.32T 11.35T 10.71T 13.53L 20.36T 1L 52.22T 7L 54.54T 53.39T 23.08L
Net Debt - -
Logo Spectral Medical Inc.
Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.
Employees
29
Date Price Change Volume
15/26/15 1.390 $ +0.72% 2,70,200
13/26/13 1.380 $ -1.43% 29,549
10/26/10 1.400 $ +1.45% 4,843
09/26/09 1.380 $ +1.47% 10,643
08/26/08 1.360 $ -2.86% 35,402
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.380CAD
Average target price
3.150CAD
Spread / Average Target
+128.26%

Quarterly revenue - Rate of surprise